Presentations.AI, a Beautiful.ai Alternative, Launches Unlimited-Seat Team Plan to Challenge Per-User Pricing, Adding Automatic Brand Sync and Document-to-Presentation Conversion Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced…
ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD
Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) today announced it has reached a manufacturing agreement…
Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced…
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
3 out of 4 intubated patients were discharged after treatment 2 out of 4 patients…
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab SAN…
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gain”) a biotechnology company…
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed…
Equillium Announces Pricing of $30 Million Registered Direct Offering
LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ) a clinical-stage…
CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a…
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT)…
TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or…
NKMax America Announces Key Leadership Appointment
SANTA ANA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — NKMax America, a biotechnology company harnessing…
G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated…
Orphazyme to showcase data on arimoclomol in Niemann-Pick disease Type C during the 2021 Annual WORLDSymposium™
Orphazyme USInvestor news …
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a…
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
Figure 1 Phase 1 study results, along with pre-clinical research, shows that CPI-006 activates antigen…
Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients
– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity without systemic IL-12 exposure – – Plan…
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical…
Kymera Therapeutics to Present at Upcoming February Investor Conferences
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical…